179 related articles for article (PubMed ID: 18154214)
1. Clinical management of EGFRI dermatologic toxicities: US perspective.
Lacouture ME; Cotliar J; Mitchell EP
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):17-21. PubMed ID: 18154214
[TBL] [Abstract][Full Text] [Related]
2. Clinical management of EGFRI dermatologic toxicities: the European perspective.
Segaert S; Van Cutsem E
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):22-6. PubMed ID: 18159647
[TBL] [Abstract][Full Text] [Related]
3. Clinical management of EGFRI dermatologic toxicities: the Japanese perspective.
Yamazaki N; Muro K
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):27-8. PubMed ID: 18159648
[TBL] [Abstract][Full Text] [Related]
4. Clinical management of EGFRI-associated dermatologic toxicities: pharmacy perspective.
Iacovelli L
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):31-3. PubMed ID: 18154216
[TBL] [Abstract][Full Text] [Related]
5. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
Tan EH; Chan A
Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
[TBL] [Abstract][Full Text] [Related]
6. Clinical management of EGFRI dermatologic toxicities: the nursing perspective.
Purdom M; Ohinata A
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):29-30. PubMed ID: 18154215
[TBL] [Abstract][Full Text] [Related]
7. Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors.
Boucher J; Olson L; Piperdi B
Clin J Oncol Nurs; 2011 Oct; 15(5):501-8. PubMed ID: 21951736
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
[TBL] [Abstract][Full Text] [Related]
9. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Mitchell EP; Perez-Soler R; Van Cutsem E; Lacouture ME
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
[TBL] [Abstract][Full Text] [Related]
10. Effects of Colloidal Oatmeal Lotion on Symptoms of Dermatologic Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors.
Ke YT; Kuo CC
Adv Skin Wound Care; 2017 Jan; 30(1):27-34. PubMed ID: 27984271
[TBL] [Abstract][Full Text] [Related]
11. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
[TBL] [Abstract][Full Text] [Related]
12. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
13. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
14. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
Wagner LI; Berg SR; Gandhi M; Hlubocky FJ; Webster K; Aneja M; Cella D; Lacouture ME
Support Care Cancer; 2013 Apr; 21(4):1033-41. PubMed ID: 23128934
[TBL] [Abstract][Full Text] [Related]
15. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy.
Fox LP
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):26-34. PubMed ID: 16736980
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
[TBL] [Abstract][Full Text] [Related]
17. Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors.
Sinclair R
Asia Pac J Clin Oncol; 2014 Mar; 10 Suppl 1():11-7. PubMed ID: 24512509
[TBL] [Abstract][Full Text] [Related]
18. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
Requena C; Llombart B; Sanmartín O
Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab-induced acneiform eruption and the response to isotretinoin.
Vezzoli P; Marzano AV; Onida F; Alessi E; Galassi B; Tomirotti M; Berti E
Acta Derm Venereol; 2008; 88(1):84-6. PubMed ID: 18176767
[No Abstract] [Full Text] [Related]
20. Clinical research of EGFR inhibitors and related dermatologic toxicities.
Perez-Soler R; Van Cutsem E
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):10-6. PubMed ID: 18154213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
